The Pharmacokinetic and Bioavailability of GenSci094 Before and After a Change in Manufacturing Site

Inclusion criteria Subjects volunteered and signed an informed consent form and were able to understand and follow the trial requirements; Healthy males aged 18-45 years old (including cut-off values); Body weight ≥60kg and BMI between 19-28 kg/m2 (including cut-off values); The subject's clinical history, physical examination, 12-lead electrocardiogram and laboratory tests during the screening period were not abnormal or the abnormalities were not clinically significant. The subject agrees to use reliable contraception for himself/herself and his/her partner for the duration of the study and for a period of 3 months after study drug infusion. Exclusion criteria Persons with clinically significant metabolic/endocrine, hepatic, renal, hematologic, pulmonary, immunologic, cardiovascular, gastrointestinal, genitourinary, neurologic, or psychiatric disorders of any clinical severity or any other condition capable of interfering with the results of the test (at the discretion of the investigator) within the 3 months prior to the Screening Period and during the Screening Period; Abnormalities in basic sex hormone tests of clinical significance (at the discretion of the investigator) Abnormal liver function: alanine aminotransferase (ALT) or alanine transaminase (AST) > 1.5 times the upper limit of normal, or total bilirubin > 1.3 times the upper limit of normal; Thromboembolic disease or history; Those with a clear history of neurologic or psychiatric disorders (including epilepsy, dementia, depression or bipolar disorder, schizophrenia, etc.); Prior history of gastrointestinal surgery, renal surgery, cholecystectomy, and other surgical procedures that, in the judgment of the investigator, may affect drug absorption or excretion; Known history of allergy, anaphylaxis or hypersensitivity to the test preparation and any of its components or related agents; Previous intolerance to phlebotomy/indwelling needle blood collection or history of blood or needle sickness; Hypertension: systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg; Positive screening tests for Hepatitis B Surface Antigen, Hepatitis C Virus Antibody, Human Immunodeficiency Virus (HIV) Antibody, or Treponema pallidum Antibody; Those who have smoked >5 cigarettes per day in the 3 months prior to screening, or who are unable to abstain from the use of any tobacco-based products during the trial period; Persons with drug dependence or drug abuse within 1 year prior to dosing, or who have a positive combined urine multi-drug test at check-in; Those who have donated blood or lost ≥ 400 mL of blood within 3 months prior to the first dose; those who have difficulty collecting blood intravenously; and those who plan to donate blood during the trial or within 1 month of the end of the study; Regular use of any prescription drug, over-the-counter drug, biologic, proprietary medicine, herbal medicine, vitamin dietary supplement or maintenance product, or vaccine within 2 weeks prior to the first dose, except for oral or buried long-acting contraceptives; Persons who have been treated with any investigational drug or medical device in a clinical trial within 3 months prior to the first dose;